Future Oncology

OCT 14, 2026 · JOURNAL ARTICLE

TroFuse-032 study design: pembrolizumab plus sacituzumab tirumotecan or chemotherapy followed by pembrolizumab plus chemotherapy as neoadjuvant therapy for early-stage, triple-negative breast cancer or HR-low+/HER2− breast cancer

Future Oncology

For most patients with high-risk, early-stage, triple-negative breast cancer (TNBC), neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab after surgery is

OCT 12, 2026 · JOURNAL ARTICLE

Plain language summary of the long-term (5 or more years) outcomes in the CARTITUDE-1 trial of ciltacabtagene autoleucel in people with relapsed or refractory multiple myeloma

Future Oncology

Plain Language SummaryWhat is this summary about?This is a summary of the long-term results in a clinical study called CARTITUDE-1. This trial tested the anti-cancer chimeric antig

OCT 1, 2026 · JOURNAL ARTICLE

Plain language summary of the J-TAIL-2 study results: a study of Japanese patients with extensive-stage small cell lung cancer that followed their treatment with atezolizumab plus chemotherapy over time

Future Oncology

Plain Language SummaryWhat is this summary about?In advanced small cell lung cancer, radiation therapy or surgery cannot eradicate the cancer because the cancer has spread widely.

SEP 22, 2026 · JOURNAL ARTICLE

Plain language summary of the RELATIVITY-098 study results: nivolumab plus relatlimab given after melanoma is removed by surgery

Future Oncology

Plain Language SummaryWhat is this summary about?In this article, we summarize the main goals and findings of the RELATIVITY-098 clinical trial, which tested whether adding relatli

SEP 16, 2026 · JOURNAL ARTICLE

Plain language summary of the ZUMA-5 study of axicabtagene ciloleucel for people with relapsed or refractory slow-growing non-Hodgkin lymphoma

Future Oncology

What is this summary about? This is a summary of a clinical study called ZUMA-5. The study looked at how well the cancer treatment axicabtagene ciloleucel (axi-cel) worked for peop

SEP 11, 2026 · JOURNAL ARTICLE

Treatment patterns after first-line abemaciclib therapy in patients with HR+, HER2− metastatic breast cancer in Japan

Future Oncology

AIMS: To determine treatment patterns following first-line abemaciclib therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+, H

SEP 10, 2026 · JOURNAL ARTICLE

A phase II study assessing the feasibility and clinical efficacy of adaptive immunotherapy combination with VEGFR-TKI in patients with advanced renal cell carcinoma

Future Oncology

Phase II feasibility and safety study of an adaptive immunotherapy-TKI combination in advanced RCC; early-stage design testing a novel treatment approach with surrogate endpoints rather than hard clinical outcomes.

SEP 9, 2026 · JOURNAL ARTICLE

Persistence and adherence to tepotinib in patients with metastatic non-small cell lung cancer: a real-world evidence study including dose reductions

Future Oncology

Real-world retrospective pharmacy data on persistence and adherence without clinical outcomes, efficacy comparison, or prospective validation; describes treatment patterns rather than clinical benefit or harm.